<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25394049</article-id><article-id pub-id-type="pmc">4224808</article-id><article-id pub-id-type="publisher-id">19541</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P050</subject></subj-group></article-categories><title-group><article-title>Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Winston</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="AF0001_19541">1</xref></contrib><contrib contrib-type="author"><name><surname>and Puls</surname><given-names>Rebekah</given-names></name><xref ref-type="aff" rid="AF0002_19541">2</xref></contrib><contrib contrib-type="author"><name><surname>CSF Sub-study</surname><given-names>group Encore</given-names></name><xref ref-type="aff" rid="AF0002_19541">2</xref></contrib></contrib-group><aff id="AF0001_19541"><label>1</label>Department of Medicine, Imperial College London, London, UK</aff><aff id="AF0002_19541"><label>2</label>Kirby Institute, TVRP, Sydney, Australia</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19541</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Winston A and Puls R; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19541"><title>Introduction</title><p>
The optimal penetration of antiretroviral agents into central nervous system (CNS) may be a balance between providing adequate drug exposure to inhibit HIV-replication whilst avoiding concentrations associated with toxicities.</p></sec><sec id="st2_19541"><title>Methods</title><p>
Cerebrospinal-fluid (CSF) exposure of efavirenz and metabolites 7-hydroxy (7OH-) and 8OH-efavirenz were assessed after at least 12 weeks of antiretroviral therapy in HIV-infected subjects randomized to commence antiretroviral regimens containing efavirenz at either 400 mg or 600 mg once daily. Clinical, pharmacokinetic and pharmacogenomic factors associated with CSF efavirenz and its metabolite concentrations were assessed.</p></sec><sec id="st3_19541"><title>Results</title><p>
Of 28 subjects who completed all study procedures (14/14 on efavirenz 400 mg/600 mg), CSF HIV RNA was below 20 copies/mL in all at the time of examination. Concentrations of efavirenz and 7OH-efavirenz in the CSF were slightly lower when dosed at 400 mg versus 600 mg, although this was not statistically significant. A different trend was observed regarding 8OH-efavirenz concentrations where CSF exposure was slightly increased in the 400 mg efavirenz arm (see <xref ref-type="table" rid="T0001_19541">Table 1</xref>). Efavirenz concentration in the CSF was above 0.51 ng/mL (proposed CSF IC50 for WT virus) in all subjects and 8OH-efavirenz concentration in the CSF was above 3.3 ng/mL (a proposed toxicity threshold, <italic>reference</italic>) in 11/14 and 7/14 subjects randomized to the 400 mg and 600 mg doses of efavirenz, respectively. Whilst CSF efavirenz concentration was significantly associated with plasma concentration (P&#x0003c;0.001) and CYP2B6 genotype (CSF efavirenz GG to GT/TT GM ratio 0.56, 90% CI 0.42&#x02013;0.74), CSF 8OH-efavirenz concentration was not (P=0.242 for association with plasma concentration and CSF 8OH-efavirenz GG to GT/TT GM ratio 1.52, 90% CI 0.97&#x02013;2.36). Lastly, CSF 8OH-efavirenz concentration was associated with efavirenz symptom questionnaire results at one year (Spearman's correlation 0.13, P=0.05).
</p></sec><sec id="st4_19541"><title>Conclusions</title><p>
With both doses of efavirenz studied, CSF concentrations were considered adequate to inhibit HIV-replication, although concentrations of 8OH-efavirenz were greater than that reportedly associated with neuronal toxicity. CSF exposure of 8OH-efavirenz was not dependent on plasma exposure and we postulate may be subject to saturable pharmacokinetic effects.</p></sec></abstract></article-meta></front><body><table-wrap id="T0001_19541" position="float"><label>Table 1</label><caption><p>CSF geometric means and ratios of efavirenz and metabolite concentrations by randomized arm (Ratios are 400/600 mg)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Geometric means (ng/mL)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="1" align="left" rowspan="1"><hr/></th><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Arm</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">90% CI (lower)</th><th align="center" rowspan="1" colspan="1">90% CI (upper)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CSF efavirenz</td><td align="center" rowspan="1" colspan="1">400 mg</td><td align="center" rowspan="1" colspan="1">16.4</td><td align="center" rowspan="1" colspan="1">13.0</td><td align="center" rowspan="1" colspan="1">20.7</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">600 mg</td><td align="center" rowspan="1" colspan="1">19.5</td><td align="center" rowspan="1" colspan="1">15.1</td><td align="center" rowspan="1" colspan="1">25.1</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ratio</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">1.18</td></tr><tr><td align="left" rowspan="1" colspan="1">CSF 7OH-efavirenz</td><td align="center" rowspan="1" colspan="1">400 mg</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">600 mg</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.40</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ratio</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.55</td><td align="center" rowspan="1" colspan="1">1.79</td></tr><tr><td align="left" rowspan="1" colspan="1">CSF 8-OH-efavirenz</td><td align="center" rowspan="1" colspan="1">400 mg</td><td align="center" rowspan="1" colspan="1">5.08</td><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">6.44</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">600 mg</td><td align="center" rowspan="1" colspan="1">3.08</td><td align="center" rowspan="1" colspan="1">2.13</td><td align="center" rowspan="1" colspan="1">4.43</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">ratio</td><td align="center" rowspan="1" colspan="1">1.65</td><td align="center" rowspan="1" colspan="1">1.09</td><td align="center" rowspan="1" colspan="1">2.5</td></tr></tbody></table></table-wrap></body><back><ref-list><title>Reference</title><ref id="CIT0001_19541"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tovar-y-Romo</surname><given-names>LB</given-names></name><name><surname>Bumpus</surname><given-names>NN</given-names></name><name><surname>Pomerantz</surname><given-names>D</given-names></name><name><surname>Avery</surname><given-names>LB</given-names></name><name><surname>Sacktor</surname><given-names>N</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>343</volume><fpage>696</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">22984227</pub-id></element-citation></ref></ref-list></back></article>